Boston Scientific (NYSE:BSX) Price Target Cut to $85.00 by Analysts at Truist Financial

Boston Scientific (NYSE:BSX) had its price objective lowered by Truist Financial from $90.00 to $85.00 in a research report released on Thursday, Marketbeat Ratings reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

BSX has been the subject of several other reports. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Morgan Stanley cut their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. Finally, Citigroup cut their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Stock Performance

Boston Scientific stock opened at $65.89 on Thursday. The company’s 50-day moving average price is $68.71 and its 200-day moving average price is $86.02. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a market cap of $97.93 billion, a PE ratio of 27.57, a price-to-earnings-growth ratio of 1.03 and a beta of 0.78. Boston Scientific has a twelve month low of $59.38 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific will post 3.36 EPS for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Hedge funds and other institutional investors have recently bought and sold shares of the business. Crown Wealth Group LLC grew its holdings in shares of Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the last quarter. Claret Asset Management Corp lifted its holdings in Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 103 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its position in Boston Scientific by 2.3% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 108 shares during the period. Finally, Kera Capital Partners Inc. grew its stake in Boston Scientific by 3.3% in the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat estimates: Boston Scientific reported $5.20B in sales (up ~11.6%) and adjusted EPS of $0.80, topping consensus and showing broad demand across key cardiovascular franchises. This underpins the bullish view on organic growth drivers. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Market reaction / reset thesis: Some analysts and outlets framed the guidance cut as a constructive “reset” that creates a buying opportunity if management executes on long-term initiatives; that framing helped shares recover after the release. Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
• Neutral Sentiment: Analysts cut targets but largely kept bullish ratings: Multiple firms trimmed price targets (Truist, Baird, Needham, Jefferies, Barclays) while maintaining buy/outperform calls — signaling shorter-term caution but continuing confidence in longer-term upside. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Broker commentary called the guidance cut “prudent” with a Q2 trough expected; analysts are modeling a weaker near term but still see recovery later in 2026. That supports mixed near-term sentiment but keeps longer-term forecasts intact. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Guidance cut: Management trimmed FY2026 EPS and revenue guidance below Street consensus and signaled softer near-term procedure volumes in some product lines — the primary reason for the re-rating and analyst target cuts. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Legal risk and class-action notices: Multiple law firms have announced investigations and class-action filings alleging misstatements around procedure demand and disclosures; this raises potential litigation costs and short-to-medium-term headline risk. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.